Clinical Trials

Inclusion Criteria:

• Clinically diagnosed pulmonary arterial hypertension (PAH) in any PAH subtype -Hemodynamic evaluation at rest at any time prior to or at the index date fulfilling all of the criteria below:
  • Mean pulmonary artery pressure greater than (>) 20 millimeters of mercury (mmHg); and
  • Pulmonary artery wedge pressure or left ventricular end diastolic pressure less than or equal to (≤) 15 mmHg; and
  • Pulmonary vascular resistance greater than or equal to (≥ 3 Wood Units (that is, ≥ 240 dynes seconds per centimeters penta [dyn∙sec/cm^5]).
• Newly initiating 1 or more PAH therapy(ies) at index date.
• All mandated assessments must be performed and recorded at the baseline visit before the initiation of the new PAH therapy at the index date.
• For the pulmonary arterial hypertension-symptoms and impact (PAH-SYMPACT) substudy only:
• Participants initiating any endothelin receptor antagonist (ERA) or phosphodiesterase-5 inhibitor therapies at index date or at therapy change must provide consent to enroll in the optional PAH-SYMPACT substudy. Refusal to give consent for the optional PAH-SYMPACT substudy will not exclude a participant from participation in the main study

Exclusion Criteria:

• Participants enrolled in any interventional clinical trial with an investigational therapy in the 3-month period prior to index date.
• Any PAH therapy initiated at index date was used by the participant (including different route of administration of the same compound) within 3 months prior to index date for any reason. (Administration for vasoreactivity testing is permitted).

Eligibility last updated 12/14/21.  Questions regarding updates should be directed to the study team contact.